Skip to main content
CSLLY logo

CSL Limited (CSLLY) Stock Price & Analysis

CSL Limited (CSLLY) — price $33.01 (+0.33%), as of the Nov 19, 2026 trading session; market cap $63.4B.

Educational signal · not a buy or sell recommendation · How to read this

$33.01 +$0.11 (+0.33%) Market Cap $63.4B

CSL Limited · CSLLY · Healthcare · Biotechnology

Research dated 2026-09-12: CSL is a scaled biopharmaceutical manufacturer whose sales come from plasma-derived and recombinant therapies, influenza-focused products, and related licensing income. Its defining financial question is whether a business that still produces substantial operating cash can restore the connection between revenue growth and net profit after a sharp earnings reversal.

Price as of Nov 19, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100
  • RPRX · Royalty Pharma plc · 73 /100
  • VRTX · Vertex Pharmaceuticals Incorporated · 90 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$33.01
Change on the day+0.33%
52-week range$16.01–$36.88
Market capitalisation$63.4B—
Price / earnings (trailing)24.09
Shares traded on the day16.0K
Beta (volatility vs the S&P 500)0.08

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $17, high $36, latest $33. $36 $17 high $36 Oct 17, 2025 Nov 19, 2026 · $33 $36Oct 17, 2025$29Oct 31, 2025$29Nov 14, 2025$31Nov 28, 2025$31Dec 12, 2025$29Dec 26, 2025$29Jan 9, 2026$31Jan 23, 2026$32Feb 6, 2026$27Feb 20, 2026$25Mar 6, 2026$24Mar 20, 2026$24Apr 2, 2026$25Apr 17, 2026$22May 1, 2026$17May 15, 2026$17May 29, 2026$19Jun 12, 2026$20Jun 26, 2026$22Jul 10, 2026$20Jul 24, 2026$24Aug 7, 2026$30Aug 21, 2026$32Sep 4, 2026$31Sep 18, 2026$31Oct 2, 2026$33Oct 16, 2026$35Oct 30, 2026$34Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for CSL (CSLLY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Weak
ROE Negative
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is CSL (CSLLY), and what does it report?

Short answer · as of

CSL Behring supplies plasma-derived and recombinant therapies for immunodeficiency, bleeding disorders, hereditary angioedema, respiratory deficiency, and neurological conditions, while Seqirus develops and supplies non-plasma biotherapeutics focused on influenza.

Licensing and royalties supplement product revenue.

Reported revenue therefore combines treatment demand across serious chronic conditions, influenza-related product demand, and intellectual-property income. CSL is better understood as a global specialty-biologics producer than as a biotechnology company whose economics depend mainly on research milestones.

2 · Latest results

What do the latest results show for CSL (CSLLY)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of $7.44B.

Annual revenue continued to rise, but the company moved from substantial net profit to a substantial net loss. In the latest reported period, revenue declined from the preceding period, gross profit contracted, operating profit weakened, and the net result turned sharply negative.

The important change is the collapse in conversion from sales and operating profit into bottom-line earnings, rather than a disappearance of revenue. Operating cash flow remained positive and increased from the preceding period, so the earnings reversal did not produce a matching collapse in cash generated by the business.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026$7.44B-$2.99B-$1.56 (diluted)
Q2 FY2026$8.30B$402M$0.05 (diluted)
Q4 FY2025$7.26B$1.03B$0.27 (diluted)
Q2 FY2025$8.21B$2.01B$0.26 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for CSL (CSLLY)?

Short answer · as of

Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.

CSL continues to generate substantial operating cash after capital expenditure, and cash has remained broadly stable across the reported window despite fluctuations between periods. Short-term liquidity appears adequate, while the quality and distress screens remain favorable.

Debt nevertheless stands far above cash and investments, leaving the balance sheet in a net-debt position. The company-specific risk is prolonged divergence between positive operating profit and negative net income: continued charges below the operating line could weaken retained financial capacity even while the core businesses remain cash generative.

4 · What to check next?

What should you watch next at CSL (CSLLY)?

Watch whether net income reconnects with operating profit, whether gross profit stabilizes as revenue changes, and whether operating cash flow continues to cover capital expenditure. Cash should also be read against debt rather than in isolation, because recent cash stability does not remove the net-debt exposure.

Research spending deserves attention alongside the earnings recovery: CSL must support plasma, recombinant, and influenza programs while protecting cash generation. Published estimates imply restrained revenue progression and only modest later earnings improvement, making the direction of actual profit conversion more informative than revenue growth alone.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • Fewer than two score snapshots exist, so no score trend is shown.

Checked against the records this page reads, on the dates shown above.

5 · Score methodology

How is CSL scored?

CSL differs from a development-stage biotechnology company because it already manufactures and distributes commercial therapies at global scale, produces operating cash, and earns some licensing and royalty income. It also differs from a narrowly focused drugmaker because plasma-derived and recombinant therapies sit alongside an influenza-focused non-plasma operation.

That structure spreads demand across rare and serious conditions and influenza products, but it also makes consolidated revenue an imperfect guide to underlying economics. Product mix, gross-profit conversion, research spending, and the gap between operating and net income matter more than pipeline headlines alone.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
argenx SE (ARGNF) Named competitor$965.00 Nov 18, 2026$60.7B— Model unavailable
Chugai Pharmaceutical Co., Ltd. (CHGCF) Named competitor$44.52 Nov 18, 2026$73.3B— Model unavailable
GSK plc (GLAXF) Named competitor$24.45 Nov 18, 2026$98.0B— Model unavailable
Genmab A/S (GNMSF) Named competitor$521.80 Nov 19, 2026$32.2B— Model unavailable
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B— 5-pillar · not comparable
Royalty Pharma plc (RPRX) Same industry, near in market value$68.67 Nov 18, 2026$39.5B— 5-pillar · not comparable
Vertex Pharmaceuticals Incorporated (VRTX) Same industry, near in market value$536.45 Nov 18, 2026$136B— 5-pillar · not comparable
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B— 5-pillar · not comparable
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B— 5-pillar · not comparable
Novo Nordisk A/S (NVO) Same industry, near in market value$39.43 Nov 18, 2026$174B— 5-pillar · not comparable
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B— 5-pillar · not comparable
Ascendis Pharma A/S (ASND) Same industry, near in market value$255.96 Nov 19, 2026$16.8B— 5-pillar · not comparable

The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CSLLY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported CSLLY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about CSL (CSLLY)?

Read these with our analysis →

What Investors Ask About CSL (CSLLY) — Healthcare

The last question is answered from this page's own dated data, not from the research.

How do CSL Behring and Seqirus differ?

CSL Behring concentrates on plasma-derived and recombinant therapies for serious medical conditions, while Seqirus focuses on non-plasma biotherapeutics related to influenza. Their revenue drivers therefore reflect different treatment categories within the same consolidated company.

What does CSL’s gap between operating profit and net loss mean?

The latest statements show that the business remained profitable at the operating line while the final result was deeply negative. Bottom-line earnings therefore deteriorated far more severely than revenue or operating activity.

Does CSL’s plasma therapy business still produce cash after the reported loss?

Consolidated operating cash flow remained substantial and exceeded capital expenditure despite the reported net loss. That cash performance separates the latest accounting loss from the cash generated by CSL’s operations, although the available figures do not isolate plasma therapies from Seqirus.

Why does CSL’s cash balance matter against its debt load?

Cash and investments provide liquidity, but they cover only a minority of total debt. CSL therefore depends more on continued operating cash generation than on its cash reserve alone when meeting financial obligations and funding investment.

What is the CSLLY stock price today?

The last price recorded for CSL Limited (CSLLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 1 from SEC filings and earnings calls, 16 from Financial Modeling Prep (FMP) and 1 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is CSL (CSLLY), and what does it report?: Business description; Sector / industry (provider taxonomy); Annual revenue and net result (USD millions); Quarterly income statement (USD thousands)
  • 2. What do the latest results show for CSL (CSLLY)?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Reported versus estimated, last 5 quarters
  • 3. What are the financial strengths and risks for CSL (CSLLY)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Distress and quality screens
  • 4. What should you watch next at CSL (CSLLY)?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and short-term investments over time (USD millions); Analyst revenue and earnings estimates (average)
  • 5. How is CSL scored?: Business description; Sector / industry (provider taxonomy); Employees; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • FAQ: How do CSL Behring and Seqirus differ?: Business description
  • FAQ: What does CSL’s gap between operating profit and net loss mean?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Trailing twelve-month ratio set; Reported versus estimated, last 5 quarters
  • FAQ: Does CSL’s plasma therapy business still produce cash after the reported loss?: Business description; Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions)
  • FAQ: Why does CSL’s cash balance matter against its debt load?: Cash, investments and debt; Cash and investment components; Cash against market value; Operating cash flow by quarter (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.